Insider · CIK 0001269340
Dennis M McGrath
directorcfopresidentofficer
Files at CTXR (Citius Pharmaceuticals, Inc.), DRIO (DarioHealth Corp.), PAVM (PAVmed Inc.), LUCD (Lucid Diagnostics Inc.), CTOR (CITIUS ONCOLOGY, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | DRIO DarioHealth Corp. | AGrant or award Common Stock | +61,000 | $0.00 | $0 | 88,737 | 14 d ago |
| Feb 20, 2026 | LUCD Lucid Diagnostics Inc. | AGrant or award Common stock | +470,000 | $0.00 | $0 | 1,813,569 | Feb 24, 2026 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 22, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 1, 2025 |
| Sep 30, 2025 | PAVM PAVmed Inc. | AGrant or award Common Stock | +150,000 | $0.00 | $0 | 200,834 | Oct 2, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Sep 23, 2025 |
| Sep 11, 2025 | DRIO DarioHealth Corp. | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 27,737 | Sep 15, 2025 |
| Dec 12, 2024 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 16, 2024 |
| Nov 7, 2024 | CTXR Citius Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.